EQL — EQL Pharma AB Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeSmall CapNeutral

Annual income statement for EQL Pharma AB, fiscal year end - March 31st, SEK millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	410	260	264	374	433
Cost of Revenue
Gross Profit	95.7	116	115	156	163
Selling / General / Administrative Expenses
Research And Development
Other Operating Expenses
Total Operating Expenses	371	219	232	306	384
Operating Profit	38.8	41.3	32.6	67.4	48.7
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	36	39	28.6	54.4	18.2
Provision for Income Taxes
Net Income After Taxes	31.5	30.9	22.7	43.1	12.5
Net Income Before Extraordinary Items
Net Income	31.5	30.9	22.7	43.1	12.5
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	31.5	30.9	22.7	43.1	12.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.09	1.05	0.781	1.48	0.438
Dividends per Share